Literature DB >> 9040715

Pain in Guillain-Barré syndrome.

D E Moulin1, N Hagen, T E Feasby, R Amireh, A Hahn.   

Abstract

OBJECTIVES: To determine the character, intensity and frequency of pain in Guillain-Barré syndrome (GBS) and to evaluate the response to treatment.
DESIGN: A prospective longitudinal study.
SETTING: Academic hospital-based practices. PATIENTS: Fifty-five consecutive patients with GBS.
INTERVENTIONS: Patients were evaluated on admission and at 2, 4, 8, 16, and 24 weeks. MAIN OUTCOME MEASURES: Character of pain, pain intensity using Visual Analogue Scale ([VAS] 0 to 10 cm) and Present Pain Intensity of McGill Pain Questionnaire, pain relief (VAS 0 to 10 cm), Disability Grading Scale for GBS.
RESULTS: Forty-nine patients (89.1%) described pain during the course of their illness. On admission, mean pain intensity (VAS) was 4.7 +/- 3.3. However, 26 patients (47.3%) described pain that was either distressing, horrible, or excruciating (mean VAS, 7.0 +/- 2.0). The most common pain syndromes observed were deep aching back and leg pain and dysesthetic extremity pain. Pain intensity on admission correlated poorly with neurologic disability on admission (r = 0.26, p = 0.06) and throughout the period of study (r < 0.20, p > 0.10). Forty-one patients (74.5%) required opioid analgesics, with 16 (29.0%) receiving parenteral morphine to provide adequate pain relief.
CONCLUSIONS: Moderate to severe pain is a common and early symptom of GBS and requires aggressive treatment. Pain intensity on admission is not a predictor of poor prognosis. Back and leg pain usually resolves over the first 8 weeks, but dysesthetic extremity pain may persist longer in 5 to 10% of patients despite motor recovery and the use of adjuvant analgesics.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9040715     DOI: 10.1212/wnl.48.2.328

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  32 in total

1.  Lesson of the week: A painful hip as a presentation of Guillain-Barré syndrome in children.

Authors:  T Tang; C Noble-Jamieson
Journal:  BMJ       Date:  2001-01-20

Review 2.  Guillain-Barré syndrome.

Authors:  U Seneviratne
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

Review 3.  Neurological diseases and pain.

Authors:  David Borsook
Journal:  Brain       Date:  2011-11-08       Impact factor: 13.501

4.  Topical diclofenac for the treatment of eyeache in Miller-Fisher syndrome.

Authors:  Ji Soo Kim; Jeong-Min Hwang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-13       Impact factor: 3.117

Review 5.  Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.

Authors:  Bianca van den Berg; Christa Walgaard; Judith Drenthen; Christiaan Fokke; Bart C Jacobs; Pieter A van Doorn
Journal:  Nat Rev Neurol       Date:  2014-07-15       Impact factor: 42.937

Review 6.  Crosstalk between the nociceptive and immune systems in host defence and disease.

Authors:  Stephen B McMahon; Federica La Russa; David L H Bennett
Journal:  Nat Rev Neurosci       Date:  2015-07       Impact factor: 34.870

Review 7.  Pharmacological treatment for pain in Guillain-Barré syndrome.

Authors:  Jia Liu; Lu-Ning Wang; Ewan D McNicol
Journal:  Cochrane Database Syst Rev       Date:  2015-04-09

8.  A rare case of Guillain-Barré syndrome presenting with abdominal pain.

Authors:  G Michas; A Nikolopoulou; E Varytimiadi; N Xydia
Journal:  Hippokratia       Date:  2015 Oct-Dec       Impact factor: 0.471

Review 9.  Respiratory dysfunction in Guillain-Barré Syndrome.

Authors:  David Orlikowski; Hélène Prigent; Tarek Sharshar; Frédéric Lofaso; Jean Claude Raphael
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

10.  Determination of pain and response to methylprednisolone in Guillain-Barré syndrome.

Authors:  Liselotte Ruts; Rinske van Koningsveld; Bart C Jacobs; Pieter A van Doorn
Journal:  J Neurol       Date:  2007-04-11       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.